2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Cervical Neoplasms: new trials by email Literature Review of Cervical Neoplasms trials Research Report on Cervical Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Cadonilimab, Nab paclitaxel - Uterine Cervical Neoplasms, Cancer of Cervix | Phase 2 | Unknown | Women's Hospital School Of Medicine Zhejiang University | 58 | 2023-06-01 | 2023-05-06 |
| Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer Sintilimab, quadrivalent HPV vaccine - Uterine Cervical Neoplasms, Cervical Cancer | Phase 2 | Unknown | Buhai Wang | 20 | 2019-07-31 | 2019-09-20 |
Uterine Cervical Neoplasms (2)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms (2) · Neoplasms by Site (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Uterine Cervical Diseases (2) · Uterine Diseases (2) · Uterine Neoplasms (2)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Taxes (1) · sintilimab (1)
Buhai Wang (1) · Women's Hospital School Of Medicine Zhejiang University (1)
China (1)
Buhai Wang (1) · Ge Lou, PHD (1) · Yuechao Wu (1)
PMID 29095678, PMID 29787422, PMID 29967015, PMID 30826965, PMID 39608975